Navigation Links
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
Date:7/30/2009

ble levels of virus at weeks 4 and 12 and to achieve SVR; (iii) Anadys' expectation that it will receive 28-day data from the 200 mg dose level by year end and additional data during the first two quarters of 2010; (iv) the antiviral and tolerability profile of ANA598 seen to date, which may not be duplicated in the Phase II study; (v) preclinical properties indicative of likely synergy when used clinically in combination regimens; and (vi) the belief that certain features of the Phase II protocol have the ability to further enhance the competitive position of ANA598. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues or will have favorable results in the planned Phase II trial. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its product candidates, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Current Report on Form 8-K filed on June 4, 2009. All fo
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
2. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
3. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
4. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
5. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
9. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Histogen, Inc., a regenerative medicine ... cells grown under simulated embryonic conditions, will present ... for melanoma during the 2015 Society of Investigative ... 2015 in Atlanta, GA. , Histogen has previously ... material with anti-oncologic properties, with potential benefit in ...
(Date:5/6/2015)... The Remedy Group , the premier provider ... pharmacy industry, will be exhibiting, presenting, and is a ... The Summit will be held May 4-8, 2015 at ... largest annual gathering for the specialty pharmacy industry. Thousands ... pharma/biotech manufacturers, and payers, to learn more about the ...
(Date:5/5/2015)... Mass. , May 5, 2015  Blueprint ... closing of its initial public offering of 9,367,708 ... price of $18.00 per share, including shares of ... the underwriters of their option to purchase additional ... offering to Blueprint Medicines were approximately $168.6 million, before ...
(Date:5/5/2015)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics ... of foodborne pathogens,  today announced that Paul G. Thomas ... 2015 Health Care Conference on May 12 at 8:00am PT. ... Las Vegas NV. ... the investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... , Michael Su, M.S. and Jin Liao, M.D., Ph.D., ... Molecular Devices Corporation, 8/00 , , INTRODUCTION ... pyralis) is very popular foruse in Reporter Gene Assays. The enzyme ... (Figure 1) 1 . When luciferase is the limiting component in ...
... Michael Su, M.S., ... 8/00 , , INTRODUCTION , ... dilutions of samples were necessary to ensure that they fell ... with greatly improved sensitivity and dynamic range, have become commercially ...
... , ... INTRODUCTION , Adenosine triphosphate (ATP) is present ... can be used as a indicator of viable cell number.ATP measurements ... contamination in the food, drug, health care and personalhealthcare industries, as ...
Cached Biology Technology:Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38) 2Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38) 3Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38) 4High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41) 2High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41) 3ATP Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #40) 2ATP Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #40) 3ATP Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #40) 4
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... HILL As vast and far-reaching as the worlds oceans ... to a study in the journal Science by researchers at ... The international team of scientists integrated global data from ... warming that threaten 20 different marine ecosystems, such as ...
... Ariz. -- If we wanted to create the ideal environmentally ... easy and economical to produce, and one that does not ... at Arizona State University intend to develop in a new ... clean fuel that produces no greenhouse gases. The ...
... 2008, 10 a.m.The Nanoscale Science, Engineering, and ... and Technology Council,s Committee on Technology ... Nanotechnology Initiatives (NNI) strategy for addressing priority ... (EHS) aspects of nanomaterials. The full ...
Cached Biology News:First map of threats to marine ecosystems shows all the world's oceans are affected 2Project focuses on production of hydrogen from bacteria and sunlight 2Project focuses on production of hydrogen from bacteria and sunlight 3Project focuses on production of hydrogen from bacteria and sunlight 4Strategy for nanotechnology-related environmental, health and safety research 2
Quantibody Human Angiogenesis Array 1 (1 slide) Class: Quantitative Antibody Arrays Product Group: Antibody Array...
BD IMagnet 1 each...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
... MW: 34.2kDa Formulation: 10mM HEPES, pH ... dithiothreitiol with 50% glycerol Properites: For ... Certificate of Analysis for individual lots ... followed by gel filtration and Mono-S ...
Biology Products: